IFP Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

IFP Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$9	Buy	+7	New	+$29	﹤0.01%	5174
2019 Q1	–	Sell	-377	Closed	-$52K	–	2923
2018 Q4	$52K	Buy	377 +250	+197%	+$42.2K	﹤0.01%	1593
2018 Q3	$32K	Buy	127 +7	+6%	+$1.94K	﹤0.01%	2165
2018 Q2	$31K	Buy	120 +110	+1,100%	+$27.2K	﹤0.01%	2205
2018 Q1	$1K	Hold	10	–	–	﹤0.01%	3639
2017 Q4	$1K	Hold	10	–	–	﹤0.01%	3691
2017 Q3	$2K	Hold	10	–	–	﹤0.01%	3751
2017 Q2	$1K	Hold	10	–	–	﹤0.01%	3900
2017 Q1	$2K	Hold	10	–	–	﹤0.01%	3657
2016 Q4	$1K	Hold	10	–	–	﹤0.01%	3796
2016 Q3	$1K	Sell	10 -33	-77%	-$3.97K	﹤0.01%	3739
2016 Q2	$4K	Buy	+43	New	+$5.59K	﹤0.01%	3250
2016 Q1	–	Sell	-33	Closed	-$7K	–	2920
2015 Q4	$7K	Buy	+33	New	+$7.14K	﹤0.01%	2768

Other funds holding KPTI

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Owl Creek Wealth Partners Denver, Colorado $355M AUM

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

MB, Levis & Associates Center Valley, Pennsylvania $273M AUM 8.08% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

IFP Advisors's KPTI Position: Q3 2026 in Review

IFP Advisors opened a new position in Karyopharm Therapeutics (KPTI) in Q3 2026: 7 shares worth $9. The stake represents ﹤0.01% of the portfolio and ranks #5174 among its holdings. This is a return to the name: IFP Advisors previously reported a position in KPTI as recently as Q4 2018.

IFP Advisors first reported a position in KPTI in Q4 2015 and has held it in 13 quarters since. The position peaked at $52K in Q4 2018. 13 funds tracked by Wall St. Rank hold KPTI as of Q3 2026.

IFP Advisors held 7 shares of Karyopharm Therapeutics worth $9 as of Q3 2026.
Karyopharm Therapeutics was a new IFP Advisors position in Q3 2026.
Karyopharm Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #5174 holding.
IFP Advisors first reported a position in Karyopharm Therapeutics in Q4 2015 and has held it in 13 quarters since.
IFP Advisors's Karyopharm Therapeutics position peaked at $52K in Q4 2018.
13 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.